• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States • Oral C5aR inhibitor…
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second…
- Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or metastatic solid tumors; initial first-in-human…
- Continued Progress in Expanding and Advancing Clinical Pipeline -- Conference Call Today at 8:30 a.m. ET - ATLANTA, Aug.…
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line setting for advanced head and…
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion regimenNKX019 clinical data presented at…
Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the…
BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and…
IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc., a medical technology company developing a user friendly, mobile and connected hemodialysis system with a category…
Financial HighlightsDirect MagnetOs sales increased by 148% from CHF 4.9 million to CHF 12.2 million, total revenue from medical devices…